CCND1 and papillary carcinoma: In the primary papillary carcinoma cells (“C1/C2”), treatment with ARV-825 (100 nM, 24h) similarly induced BRD4 protein degradation as well as downregulation of c-Myc, Bcl-xL and cyclin D1 (Figure 3F).